Journey Medical (DERM) vs Emmis Acquisition (EMIS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Journey Medical is the larger company by market cap ($167.9 million vs $162.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DERM | EMIS |
|---|---|---|
| Share price | $5.95 | $10.27 |
| Market cap | $167.94M | $162.02M |
| 1-day change | -3.41% | 0.00% |
| YTD return | -22.83% | +3.22% |
| 1-year return | -21.19% | — |
| EPS (TTM) | $-0.21 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.56 | $10.27 |
| 52-week low | $4.31 | $9.90 |
| Distance from 52-week high | -37.73% | 0.00% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +131.09% | — |
| Average volume | 181.79K | 13.89K |
| Shares outstanding | 22.22M | 11.94M |
| Employees | 58 | — |
| Sector | Healthcare | Financial Services |
| Industry | Drug Manufacturers - Specialty & Generic | Shell Companies |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Journey Medical in Healthcare and Emmis Acquisition in Financial Services.
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Healthcare · Drug Manufacturers - Specialty & Generic · 58 employees
About Emmis Acquisition
EMIS stock →Emmis Acquisition Corp. focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
Financial Services · Shell Companies
DERM vs EMIS FAQ
Which is bigger, Journey Medical or Emmis Acquisition?
Journey Medical (DERM) is larger, with a market capitalization of $167.94M compared with $162.02M for Emmis Acquisition (EMIS).
Are Journey Medical and Emmis Acquisition in the same industry?
No. Journey Medical is in the Healthcare sector, while Emmis Acquisition is in Financial Services.